{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-073391","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.565623+00:00","generated_at":"2026-05-15T23:36:52.193563+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Viridian reports 2025 net loss of $342.6M; veligrotug PDUFA date June 30, 2026","bullets":["Cash, cash equivalents and marketable securities were $874.7M as of Dec 31, 2025, up from $717.6M.","Net loss for 2025 was $342.6M ($269.9M in 2024); R&D spend rose to $338.9M.","PDUFA target action date for veligrotug BLA is June 30, 2026; Priority Review ongoing.","MAA for veligrotug submitted to EMA in January 2026 for European approval.","Phase 3 REVEAL-1 topline data for elegrobart on track for Q1 2026; REVEAL-2 for Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-073391","json":"https://secwatch.observer/filing/0001193125-26-073391.json","markdown":"https://secwatch.observer/filing/0001193125-26-073391.md","text":"https://secwatch.observer/filing/0001193125-26-073391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/0001193125-26-073391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/d105707d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:36:52.193563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}